Search results for "adrenal"

showing 10 items of 416 documents

Complications in Immunosuppressive Therapy of Liver Transplant Recipients

2011

BACKGROUND: In liver transplantation (LT), modern immunosuppressive protocol is focused on early corticosteroid (CS) weaning. The aim of the study was to investigate all early transplant-related complications using Clavien grading system, in order to identify a significant relation in two homogenous groups of consecutive liver transplanted patients, only different for steroid avoidance in immunosuppressive regimen. MATERIALS AND METHODS: One group was treated with a tacrolimus-based CS-free immunosuppressive protocol, the other one underwent tacrolimus plus low dose CS therapy. The preoperative continuous variables analyzed were age, gender, model for end-stage liver disease (MELD) score, a…

AdultGraft RejectionMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicatecomplicationLiver transplantationGastroenterologyTacrolimusYoung AdultLiver diseasePostoperative ComplicationsAdrenal Cortex HormonesInternal medicinemedicineHumansAgedRetrospective Studiesimmunosuppressionbusiness.industryIncidenceLiver DiseasesIncidence (epidemiology)ImmunosuppressionMiddle Agedmedicine.diseaseTacrolimusLiver TransplantationSurgerySurvival RateRegimenCorticosteroidDrug Therapy CombinationFemaleSurgeryrejectionComplicationbusinessImmunosuppressive AgentsJournal of Surgical Research
researchProduct

Tacrolimus Monotherapy Without Steroids After Liver Transplantation – A Prospective Randomized Double-Blinded Placebo-Controlled Trial

2007

Early steroid withdrawal after liver transplantation (LT) is desirable in order to reduce steroid side effects. Between February 2000 and August 2004, 110 patients after LT were included in this prospective, randomized, double-blind, placebo-controlled trial. Randomization was performed before LT. In all patients, tacrolimus was used without induction therapy. All patients received methylprednisolon for 14 days, thereafter a double-blinded medication containing either placebo (n = 56) or methylprednisolon (n = 54) for 6 months, which was completely stopped thereafter. End points were patient and graft survival, acute and chronic rejection, and incidence of steroid side effects during the fi…

AdultGraft RejectionMalemedicine.medical_specialtyTime FactorsRandomizationmedicine.drug_classmedicine.medical_treatmentPlacebo-controlled studyLiver transplantationPlaceboMethylprednisoloneGastroenterologyTacrolimuslaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicinemedicineHumansImmunology and AllergyPharmacology (medical)Antibacterial agentTransplantationbusiness.industryMiddle AgedTacrolimusLiver TransplantationSurgeryCorticosteroidFemaleSafetybusinessImmunosuppressive AgentsFollow-Up StudiesAmerican Journal of Transplantation
researchProduct

Pituitary-adrenal responses to corticotropin-releasing factor in late onset 21-hydroxylase deficiency

1990

Intravenous corticotropin-releasing factor (CRF) and adrenocorticotropin hormone (ACTH) were administered in patients with adult onset 21-hydroxylase deficiency to compare their diagnostic capability as well as to investigate hypothalamic-pituitary-adrenal function in this disorder. Responses of 17-hydroxyprogesterone, which were markedly elevated compared with controls, were identical with CRF and ACTH. However, intravenous ACTH resulted in higher androstenedione levels in comparison to CRF. Adrenocorticotropin hormone also resulted in decreased cortisol responses, confirming a defect in steroidogenesis, a finding that was not evident with CRF. Plasma ACTH responses to CRF were similar in …

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentCorticotropin-Releasing HormoneLate onsetPeptide hormoneDecreased cortisolAdrenocorticotropic HormoneInternal medicineAdrenal GlandsHydroxyprogesteronesmedicineHumansTestosteroneIn patientAndrostenedioneAdrenal Hyperplasia Congenitalbiologybusiness.industry17-alpha-HydroxyprogesteroneAndrostenedione21-HydroxylaseObstetrics and GynecologyDiagnostic testEndocrinologyReproductive MedicinePituitary GlandSteroid Hydroxylasesbiology.proteinFemalebusinesshormones hormone substitutes and hormone antagonistsHormoneFertility and Sterility
researchProduct

The endocrine pattern of late onset adrenal hyperplasia (21-hydroxylase deficiency)

1984

We describe 5 adult women with severe hirsutism due to late onset 21-hydroxylase deficiency. Diagnosis was performed on the finding of high serum 17-hydroxyprogesterone (17OHP) levels with a marked hyperresponse to an ACTH test. The endocrine study showed in most patients a gonadotropin behavior similar to that observed in classical polycystic ovary (PCO) syndrome. Prolactin levels were slightly increased in basal conditions and presented an exaggerated response to TRH stimulation.

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismLate onsetEndocrinologyAdrenocorticotropic HormoneInternal medicineHydroxyprogesteronesmedicineHumansEndocrine systemGonadal Steroid HormoneshirsutismAdrenal Hyperplasia Congenitalbiologybusiness.industry17-alpha-HydroxyprogesteroneVirilization21-HydroxylaseLuteinizing Hormonemedicine.diseasePolycystic ovaryProlactinProlactinEndocrinologySteroid Hydroxylasesbiology.proteinFemaleSteroid 21-HydroxylaseFollicle Stimulating Hormonemedicine.symptomGonadotropinbusinesshormones hormone substitutes and hormone antagonistsJournal of Endocrinological Investigation
researchProduct

Prevalence of late-onset 11 β-hydroxylase-deficiency in hirsute patients

1988

Serum levels of 11-deoxycortisol were determined in 182 hirsute women. Three patients presented high basal 11-deoxycortisol levels and an exaggerated response of this steroid to ACTH stimulation. A fourth patient had normal basal 11-deoxycortisol but was hyperresponsive to ACTH stimulation. Therefore diagnosis of late-onset 11 beta-hydroxylase deficiency was made in 4 out of 182 hirsute women with a prevalence of 2.2% in the group studied. In these patients, clinical findings and other hormonal patterns were not different from those of other women suffering from hirsutism.

AdultHirsutismendocrine systemmedicine.medical_specialtyTime FactorsAdolescentEndocrinology Diabetes and MetabolismLate onset11-Deoxycortisolchemistry.chemical_compoundBasal (phylogenetics)EndocrinologyInternal medicinemedicineHumansSicilyActh stimulationhirsutismAdrenal Hyperplasia Congenitalbusiness.industryHydroxylase deficiencyHyperandrogenismmedicine.diseaseEndocrinologychemistrySteroid HydroxylasesFemalebusinessHormoneJournal of Endocrinological Investigation
researchProduct

Update on autoimmune hepatitis

2009

Autoimmune hepatitis (AIH) is a necroinflammatory liver disease of unknown etiology that occurs in children and adults of all ages. Characteristics are its autoimmune features, hyperglobulinemia (IgG), and the presence of circulating autoantibodies, as well as a response to immunosuppressant drugs. Current treatment consists of prednisone and azathioprine and in most patients this disease has become very treatable. Over the past 2 years, a couple of new insights into the genetic aspects, clinical course and treatment of AIH have been reported, which will be the focus of this review. In particular, we concentrate on genome-wide microsatellite analysis, a novel mouse model of AIH, the evaluat…

AdultHyperglobulinemiaAzathioprineAutoimmune hepatitisDiseaseAntibodiesLiver diseaseLife ExpectancyAdrenal Cortex Hormonesimmune system diseasesPrednisonemedicineHumansSurvivorsChildHepatitisGenome Humanbusiness.industryHistocompatibility Antigens Class IHistocompatibility Antigens Class IIThyroiditis AutoimmuneGastroenterologyAutoantibodyDNAGeneral Medicinemedicine.diseasedigestive system diseasesHepatitis AutoimmuneEditorialImmunoglobulin GImmunologybusinessImmunosuppressive AgentsMicrosatellite Repeatsmedicine.drugWorld Journal of Gastroenterology
researchProduct

Cortisol levels and seizures in adults with epilepsy: A systematic review

2018

Stress has been suggested as a trigger factor for seizures in epilepsy patients, but little is known about cortisol levels, as indicators of stress, in adults with epilepsy. This systematic review summarizes the evidence on this topic. Following PRISMA guidelines, 38 articles were selected: 14 analyzing basal cortisol levels, eight examining antiepileptic drugs (AEDs) effects, 13 focused on seizure effects, and three examining stress. Higher basal cortisol levels were found in patients than in healthy people in studies with the most homogeneous samples (45% of 38 total studies). Despite heterogeneous results associated with AEDs, seizures were related to increases in cortisol levels in 77% …

AdultHypothalamo-Hypophyseal SystemEpilepsyHydrocortisonebusiness.industryCognitive NeurosciencePhysiologymedicine.diseaseBehavioral NeuroscienceEpilepsyFunctional brainBasal (phylogenetics)Neuropsychology and Physiological Psychologymedicine.anatomical_structureSeizuresHomogeneousmedicineHumansAnticonvulsantsChronic stressAcute stressbusinessCortisol levelStress PsychologicalHypothalamic–pituitary–adrenal axisNeuroscience & Biobehavioral Reviews
researchProduct

Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease

2022

Abstract Objective To compare clinical features and treatments of patients with systemic JIA (sIJA) and adult-onset Still’s disease (AOSD). Methods The clinical charts of consecutive patients with sJIA by International League of Association of Rheumatology criteria or AOSD by Yamaguchi criteria were reviewed. Patients were seen at a large paediatric rheumatology referral centre or at 10 adult rheumatology academic centres. Data collected included clinical manifestations, inflammation biomarkers, systemic score, macrophage activation syndrome (MAS), parenchymal lung disease, disease course, disability, death and medications administered. Results A total of 166 patients (median age at diagnos…

AdultLung DiseasesBiological ProductsMacrophage Activation SyndromeArthritis JuvenileSystemic juvenile idiopathic arthritis; adult-onset Still’s diseaseRheumatologyAdrenal Cortex HormonesSystemic juvenile idiopathic arthritisAntirheumatic AgentsFerritinsPrevalenceSystemic juvenile idiopathic arthritiHumansadult-onset Still’s diseasePharmacology (medical)ChildStill's Disease Adult-OnsetBiomarkersAcute-Phase Proteins
researchProduct

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

2021

Abstract Introduction With the increasing use of checkpoint inhibitors, rare immune-related adverse events (irAE) are being identified. Haematological irAE (hem-irAE) are difficult to treat and have shown high mortality rates. In order to improve side-effect management for these potentially life-threatening events, we analysed frequency, severity and outcomes. Patients and methods Patients who developed hem-irAE while being treated with immune checkpoint inhibitors (ICI) therapy were retrospectively identified from 18 international cancer centres. Results In total, more than 7626 patients treated with ICI were screened, and 50 patients with hem-irAE identified. The calculated incidence amou…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyNeutropeniamedicine.medical_treatmentMedizinNeutropeniamedicine.disease_causeGastroenterologyAutoimmunityYoung Adult03 medical and health sciences0302 clinical medicineImmune systemAdrenal Cortex HormonesInternal medicinemedicineHumansAdverse effectImmune Checkpoint InhibitorsAgedRetrospective StudiesAged 80 and overHemophagocytic lymphohistiocytosisbusiness.industryIncidenceIncidence (epidemiology)CancerAnemiaImmunosuppressionMiddle Agedmedicine.diseaseThrombocytopeniaTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemalebusinessImmunosuppressive Agents
researchProduct

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma

2018

Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects.This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance OCS treatment plus inhaled corticosteroids/long-acting β2-agonists. Overall, 140 patients were randomised to tralokinumab 300 mg or placebo (n=70 in each group) administered subcutaneously every 2 weeks. The primary end-point was percentage change from baseline in average OCS dose at week 40, while maintaining asthma control. Secondary end-points included proportion of patients with a prescribed maintenance OCS do…

AdultMale0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classAdministration OralPlacebolaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsAdverse effectAgedInhalationRespiratory tract infectionsbusiness.industryAntibodies MonoclonalMiddle AgedAsthmaClinical trialTreatment Outcome030104 developmental biology030228 respiratory systemDisease ProgressionCorticosteroidFemalebusinessTralokinumabEuropean Respiratory Journal
researchProduct